MX2020014097A - Lipidos novedosos. - Google Patents
Lipidos novedosos.Info
- Publication number
- MX2020014097A MX2020014097A MX2020014097A MX2020014097A MX2020014097A MX 2020014097 A MX2020014097 A MX 2020014097A MX 2020014097 A MX2020014097 A MX 2020014097A MX 2020014097 A MX2020014097 A MX 2020014097A MX 2020014097 A MX2020014097 A MX 2020014097A
- Authority
- MX
- Mexico
- Prior art keywords
- novel lipids
- lipids
- novel
- present
- invention includes
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención incluye un compuesto que tiene la siguiente fórmula estructural: (ver Fórmula).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690196P | 2018-06-26 | 2018-06-26 | |
| US16/452,858 US10975111B2 (en) | 2018-06-26 | 2019-06-26 | Cardiopathy-reducing phosphodiester lipids |
| PCT/US2019/039162 WO2020006033A1 (en) | 2018-06-26 | 2019-06-26 | Novel lipids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020014097A true MX2020014097A (es) | 2021-04-13 |
Family
ID=68980509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020014097A MX2020014097A (es) | 2018-06-26 | 2019-06-26 | Lipidos novedosos. |
| MX2023014281A MX2023014281A (es) | 2018-06-26 | 2020-12-17 | Lipidos novedosos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014281A MX2023014281A (es) | 2018-06-26 | 2020-12-17 | Lipidos novedosos. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10975111B2 (es) |
| EP (1) | EP3813820A4 (es) |
| JP (2) | JP7325840B2 (es) |
| KR (1) | KR102627389B1 (es) |
| CN (1) | CN112367986A (es) |
| AU (2) | AU2019291808A1 (es) |
| CA (1) | CA3103918C (es) |
| MX (2) | MX2020014097A (es) |
| TW (1) | TWI731336B (es) |
| WO (1) | WO2020006033A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI731336B (zh) | 2018-06-26 | 2021-06-21 | 美商標徑製藥公司 | 新穎脂質 |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| CA3207493A1 (en) * | 2021-01-29 | 2022-08-04 | Signpath Pharma, Inc. | Lipids that reduce lung damage, improve pulmonary function and decrease pro-inflammatory cytokines |
| KR20230147184A (ko) * | 2021-03-03 | 2023-10-20 | 사인패스 파마 인코포레이티드 | 인간에서의 악성 흉막 삼출 치료 |
| TW202417005A (zh) * | 2022-09-22 | 2024-05-01 | 美商標徑製藥公司 | 保護心臟之脂質及使用方法 |
| WO2025049064A2 (en) * | 2023-08-28 | 2025-03-06 | Signpath Pharma Inc. | Cardioprotective lipids and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049587A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Process for preparation of biphenyl tetrazole |
| EP1819715A4 (en) | 2004-11-08 | 2010-02-17 | Neopharm Inc | SYNTHESIS OF CARDIOLIPINANALOGA AND APPLICATIONS THEREOF |
| US10117881B2 (en) * | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
| ES2940564T3 (es) | 2013-12-18 | 2023-05-09 | Signpath Pharma Inc | Mitigación liposómica de la inhibición inducida por fármaco del canal IKr cardíaco |
| ES2942132T3 (es) | 2014-06-03 | 2023-05-30 | Signpath Pharma Inc | Efecto protector de DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG y LYSOPC frente a fármacos que provocan canalopatías |
| CN105273001A (zh) | 2014-07-21 | 2016-01-27 | 南京绿叶制药有限公司 | 一种合成磷脂酰甘油单钠盐的方法 |
| CN105985373A (zh) | 2015-04-10 | 2016-10-05 | 江苏东南纳米材料有限公司 | 一种制备（r）-1,2-二脂肪酸甘油磷酯酰甘油酯的新方法 |
| CN106188169B (zh) * | 2016-07-07 | 2019-06-25 | 沈阳药科大学 | 一种含有唾液酸基团的脂质衍生物的合成及其在药物制剂中的应用 |
| US20190008878A1 (en) * | 2017-07-07 | 2019-01-10 | Signpath Pharma Inc. | Compositions and method for reducing cardiotoxicity |
| TWI731336B (zh) | 2018-06-26 | 2021-06-21 | 美商標徑製藥公司 | 新穎脂質 |
-
2019
- 2019-05-24 TW TW108117980A patent/TWI731336B/zh active
- 2019-06-26 AU AU2019291808A patent/AU2019291808A1/en not_active Abandoned
- 2019-06-26 WO PCT/US2019/039162 patent/WO2020006033A1/en not_active Ceased
- 2019-06-26 JP JP2020569849A patent/JP7325840B2/ja active Active
- 2019-06-26 MX MX2020014097A patent/MX2020014097A/es unknown
- 2019-06-26 EP EP19826650.4A patent/EP3813820A4/en active Pending
- 2019-06-26 CA CA3103918A patent/CA3103918C/en active Active
- 2019-06-26 US US16/452,858 patent/US10975111B2/en active Active
- 2019-06-26 CN CN201980043031.6A patent/CN112367986A/zh active Pending
- 2019-06-26 KR KR1020217000558A patent/KR102627389B1/ko active Active
-
2020
- 2020-12-17 MX MX2023014281A patent/MX2023014281A/es unknown
-
2021
- 2021-03-03 US US17/191,214 patent/US11643424B2/en active Active
- 2021-11-05 US US17/520,287 patent/US11746119B2/en active Active
-
2022
- 2022-07-17 AU AU2022205275A patent/AU2022205275B2/en active Active
-
2023
- 2023-07-25 JP JP2023121064A patent/JP7646233B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11643424B2 (en) | 2023-05-09 |
| JP7325840B2 (ja) | 2023-08-15 |
| EP3813820A4 (en) | 2022-05-04 |
| TW202019404A (zh) | 2020-06-01 |
| KR102627389B1 (ko) | 2024-01-19 |
| AU2022205275B2 (en) | 2024-05-30 |
| US20210198294A1 (en) | 2021-07-01 |
| US20220056057A1 (en) | 2022-02-24 |
| WO2020006033A1 (en) | 2020-01-02 |
| KR20210018926A (ko) | 2021-02-18 |
| US20190389888A1 (en) | 2019-12-26 |
| AU2019291808A1 (en) | 2021-01-14 |
| CA3103918C (en) | 2023-09-19 |
| CN112367986A (zh) | 2021-02-12 |
| JP7646233B2 (ja) | 2025-03-17 |
| US11746119B2 (en) | 2023-09-05 |
| JP2021534076A (ja) | 2021-12-09 |
| MX2023014281A (es) | 2024-01-17 |
| AU2022205275A1 (en) | 2022-08-11 |
| JP2023153882A (ja) | 2023-10-18 |
| CA3103918A1 (en) | 2020-01-02 |
| EP3813820A1 (en) | 2021-05-05 |
| TWI731336B (zh) | 2021-06-21 |
| US10975111B2 (en) | 2021-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020014097A (es) | Lipidos novedosos. | |
| ZA202102549B (en) | Substituted tolyl as fungicides | |
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| PH12020500655A1 (en) | Compounds | |
| PH12018501096A1 (en) | Modulators of chemokine receptors | |
| AU2018258581A8 (en) | RAF-degrading conjugate compounds | |
| MY203303A (en) | Compounds | |
| EA201992177A1 (ru) | Композиции на основе нирапариба | |
| AU2018293627A1 (en) | New azaquinoline derivatives | |
| CA185542S (en) | Table | |
| MX2020010657A (es) | Derivados de oxadiazolina. | |
| PH12021550102A1 (en) | Cardiosafe antidiabetic therapy | |
| ZA202309446B (en) | Rapamycin analogs and uses thereof | |
| UA120058C2 (uk) | Пестицидні композиції | |
| MX2017014549A (es) | Farmacos precursores de oxabicicloheptanos. | |
| SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| ZA202101487B (en) | Novel compounds | |
| EA202190475A1 (ru) | Мини-gde для лечения гликогеноза iii типа | |
| EA201991241A1 (ru) | Способ получения метоксиметилпиридин дикарбоксилата | |
| MY188420A (en) | Crystalline forms of (s)-afoxolaner | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
| MX2018011877A (es) | Proceso mejorado para la preparacion de tartrato de butorfanol. | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| MX2019004182A (es) | Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al. | |
| ZA202205170B (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine |